HBHikmettullah Batgi

Hikmettullah Batgi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hikmettullah Batgi has a total of 58 co-authors. Here are the top co-authors by number of shared publications:

  • Semih Başcı

    Department of Hematology, Faculty of Medicine, Dokuz Eylül University, 35340 İzmir, Türkiye

    7 shared publications
  • Mehmet Sinan Dal

    University of Health Sciences, Ankara Oncology Training and Research Hospital, Department of Hematology & Apheresis Unit, Ankara, Türkiye

    6 shared publications
  • Bahar Uncu Ulu

    Hematology and Bone Marrow Transplantation Unit, Ankara Oncology Training and Research Hospital, Health Sciences University, Ankara 06170, Turkey

    4 shared publications
  • Dicle İsKender

    Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey

    4 shared publications
  • Fevzi Altuntaş

    Hematology and Bone Marrow Transplantation Unit, Ankara Oncology Training and Research Hospital, Health Sciences University, Ankara 06170, Turkey

    4 shared publications
  • Mehmet Sinan Dal

    Department of Hematology & Apheresis Unit, Ankara Oncology Training and Research Hospital, University of Health Sciences, 06200 Ankara, Türkiye

    4 shared publications

Latest Publications

  • Open Access

    Elranatamab in relapsed/refractory multiple myeloma patients on hemodialysis: A real-world case series

    by Hikmettullah Batgi, Fatoş Dilan Köseoğlu, Denis Çetin, Semih Başcı, Sinem Namdaroğlu, Nur Akad Soyer

    Background: Renal impairment is a frequent and adverse prognostic factor in multiple myeloma (MM), with dialysis-dependent patients largely excluded from pivotal trials of B-cell maturation antigen (BCMA)-directed therapies. Elranatamab, a BCMA×CD3 bispecific antibody, has demonstrated significant efficacy in relapsed/refractory multiple myeloma (RRMM); however, data in end-stage renal disease are extremely limited. We report real-world outcomes of four dialysis-dependent RRMM patients treated with elranatamab. Results: Patients with a median age of 67 years (range 61–80) had received a median of six prior lines of therapy (range 4–7). All were refractory to proteasome inhibitors, immunomodulatory drugs, and anti-CD38 therapy, and none had prior BCMA-directed treatment. Baseline glomerular filtration rate ranged from 5 to 20 mL/min, and all patients were dialysis-dependent. At data cutoff, all four patients were evaluable for response. Two patients achieved complete response (CR), one achieved very good partial response, and one achieved partial response, resulting in an overall response rate of 100%. Treatment was ongoing in all four patients. Cytokine release syndrome (CRS) occurred in one patient (grade 1) and was self-limited. No immune effector cell-associated neurotoxicity syndrome (ICANS) events were observed. One patient developed severe pneumonia requiring intensive care unit admission; treatment was temporarily interrupted and successfully resumed without step-up dosing, maintaining CR. Hematologic toxicity was limited, with grade-4 lymphopenia in one patient. No dialysis-related complications or unexpected toxicities were observed. All patients received infection prophylaxis after hemodialysis, including trimethoprim–sulfamethoxazole, valacyclovir, and levofloxacin, with intravenous immunoglobulin administered. Conclusion: In this real-world case series of dialysis-dependent RRMM patients, elranatamab demonstrated high response rates, low incidence of CRS, absence of neurotoxicity, and manageable infectious complications. These findings support the feasibility and clinical activity of elranatamab in patients undergoing hemodialysis. Larger prospective studies are warranted to confirm these encouraging results.

  • Open Access

    Cryopreservation of CD34+ Hematopoietic Stem Cells Using Cryofit® DMSO and Its Outcomes

    by Semih Başcı, Hikmettullah Batgi, Sinem Namdaroğlu

    Objective: Autologous hematopoietic stem cell transplantation (auto-SCT) is a key treatment for hematological malignancies and immune disorders. Cryopreservation of CD34+ hematopoietic stem cells (HSCs) ensures transplant success. Dimethyl sulfoxide (DMSO) is a widely used cryoprotectant but can cause infusion-related toxicities. CryoFit® DMSO aims to enhance cell viability while reducing adverse effects. This study evaluates its efficacy and safety in auto-SCT. Material and Method: A single-center, retrospective study was conducted on 80 patients who underwent auto- SCT with CD34+ HSCs cryopreserved using CryoFit® DMSO. Mobilization was performed using granulocyte colony-stimulating factor (G-CSF) ± chemotherapy and plerixafor when required. CD34+ cells were quantified via flow cytometry before cryopreservation. Post-transplant engraftment, transfusion needs, and infusion-related side effects were assessed. Data analysis was conducted using SPSS 26.0. Results: The median patient age was 58.5 years (range: 19-75) and 53.8% (n=43) of the cohort sample was female. Multiple myeloma was the most common diagnosis (57.5%). The median collected CD34+ cell count was 5.8 x 106/ kg (range: 3.2-14). Post-thaw viability was 98% (range: 90-99.5%). Neutrophil and platelet engraftment occurred at medians of 13 and 17 days, respectively. The median hospitalization duration was 24 days (range: 15-60). Infusion-related adverse effects occurred in 26.3% of patients, primarily nausea/vomiting (15%), all manageable. Conclusion: CryoFit® DMSO effectively preserves CD34+ HSCs with high post-thaw viability and favorable engraftment. Mild infusion-related toxicities were observed but were transient. The results support its continued use in auto-SCT. Further multicenter studies are required to optimize cryopreservation protocols.

  • The impact of second allogeneic hematopoietic stem cell transplantation as salvage therapy for hematologic diseases after a first allogeneic transplantation

    by Hikmetullah Batgi, Tuğba Zorlu, Mehmet Ali Erkurt, Ant Uzay, Ipek Yonal Hindilerden, Mehmet Sezgin Pepeler, Merve Apaydin, Yavuz Katircilar, Mustafa Koroglu, Emin Kaya, et al.

  • Open Access

    Comparison of Clinical and Hematological Parameters of Janus Kinase 2, Calreticulin or Myeloproliferative Leukemia Virus Oncogene Mutant Essential Thrombocythemia and Triple-Negative Essential Thrombocythemia

    by Jale Yıldız, Hikmettullah Batgi

    Essential thrombocythemia (ET) is one of the chronic myeloproliferative neoplasms. While Janus kinase 2 (JAK2) V617F mutation is defined in more than half of the patients with ET, calreticulin (CALR) or myeloproliferative leukemia virus oncogene (MPL) mutations are encountered more rarely. The discovery of the JAK2 V617F mutation in 2005, followed by the recognition of MPL and CALR mutations, brought up the idea of subdividing ET according to the mutation status. Our aim in this study is to investigate whether genetic mutations detected in patients diagnosed with ET cause a different clinical phenotype compared to triple-negative ET. This retrospective study was conducted by evaluating the patients who were followed up with the diagnosis of ET in the hematology clinic of two tertiary centers in Turkey between 2009 and 2021. Patients with negative JAK2, CALR, and MPL mutations and meeting the diagnostic criteria for ET were defined as triple-negative ET. The patients were divided into two groups as triple-negative ET and mutation-positive ET according to the presence of a mutation. It was investigated whether there was a difference between these two groups in terms of demographic, laboratory, and clinical characteristics. A total of 109 patients were included in the study. The mean age of these patients was 54 (18-91) years and 85 (78%) patients were females. A total of 48 patients (44.0%) had JAK2 mutation, six (5.5%) had CALR mutation, and one (0.9%) had MPL mutation. It was observed that there was a significant difference between the two groups in terms of gender, mean age, and hemoglobin value. While 87% of patients with triple-negative ET were females, this rate was 69% in patients with mutation-positive ET (p = 0.036). The mean age was 41.8 years in triple-negative ET and 67.1 years in patients with mutation-positive ET (p = 0.0001). While the mean hemoglobin value was 12.9 g/dl in patients with triple-negative ET, it was 14.4 g/dl in patients with mutation-positive ET (p = 0.0001). It has been observed that ET with JAK2, CALR, or MPL mutations may have different phenotypic features compared to triple-negative ET, resulting in a clinical condition consisting of older patients with a higher erythrocyte count.

  • Evaluation of Thromboembolism According to Mutation Status in Patients with Essential Thrombocytosis; Single-Center Experience

    by Hikmettullah Batgi̇

    Aim: The presence of Janus kinase 2 (Jak2) mutation in essential thrombocytosis (ET) patients is associated with an increased risk of thrombosis, while the presence of calreticulin (Calr) mutation is associated with a decrease in thrombosis risk. The aim of this study is to compare patients with mutation (Jak2, Calr, myeloproliferative leukemia virus oncogene [Mpl]) and non-mutation (triple-negative) patients in terms of the development of thromboembolism. Methods: 95 patients who were followed up with the diagnosis of ET between 2009 and 2020 were included in this study. The clinical characteristics, laboratory results, and mutation status of the patients were analyzed retrospectively, based on the patients’ files. The patients in mutation positive (Jak2, Calr, Mpl) group a, only jak2 mutation-positive group b, and triple-negative (Jak2, Calr, Mpl negative) group c were compared. Results: The median age of ET patients was 53 years (18-91). The Jak2 mutation was found positive in 42% (n:40) of the patients with ET. 4 patients (4%) were calr mutation-positive, but mpl mutation was not detected. 51 patients (54%) were triple-negative. A total of 22 (23%) patients had a thrombotic event at diagnosis and follow-up. Thrombotic events were detected in 27.5% (11/44) of the patients with positive Jak2 mutation and in 21.5% (11/51) of the patients with triple-negative. No thrombotic event was detected in 4 patients with a positive calr mutation. No statistically significant difference was found for thrombotic events in mutation-positive patients compared with triple-negative patients (p = 0.7). No statistically significant difference was found in terms of white blood cell count, thrombocyte count and spleen size examined at the time of diagnosis. When compared in terms of hemoglobin, age and gender distribution (male / female), the difference was found statistically significant in those with positive mutation (p = 0.001 *, p = 0.001 *, p = 0.03*). Discussion and Conclusion: The results of this study showed that Jak2V617F gene mutation is an important finding for diagnosis and complications in patients with ET, and its presence increases the risk of thrombosis development. The presence of calr mutation reduces the risk of thrombosis and appears at an earlier age than Jak2V617F mutation. Thrombosis risk in triple-negative ET patients is similar to the one in patients with Jak2V617F mutation.

  • Extracorporeal photopheresis in the treatment of acute graft-versus-host disease: A multicenter experience

    by Hikmettullah Batgi, Mehmet Sinan Dal, Mehmet Ali Erkurt, Irfan Kuku, Erdal Kurtoglu, Ipek Yonal Hindilerden, Emin Kaya, Ilhami Berber, Turgay Ulas, Fevzi Altuntas


  • Extracorporeal photopheresis in steroid-refractory chronic graft-versus-host disease: A retrospective multicenter study

    by Mehmet Sinan Dal, Hikmettullah Batgi, Mehmet Ali Erkurt, Ipek Yonal Hindilerden, Irfan Kuku, Erdal Kurtoglu, Emin Kaya, Sevgi Kalayoglu Besisik, Ilhami Berber, Meliha Nalcaci, et al.


  • Open Access

    Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience

    by Hikmettullah Batgi̇, Semih Başci, Mehmet Sinan Dal, Merih Kizil Çakar, Bahar Uncu Ulu, Tuğçe Nur YİĞENOĞLU, Nurgül Özcan, Ali Kilinç, Alparslan Merdi̇n, Jale Yildiz, et al.

    GDP (gemcitabine, dexamethasone and cisplatin) is a well-established salvage regimen for relapsed and refractory lymphomas. In this study, we aimed to share our experience with the patients who received GDP/R-GDP (rituximab-gemcitabine, dexamethasone and cisplatin) for stem cell mobilization. Data of 69 relapsed and refractory Hodgkin lymphoma (HL) and Non-Hodgkin lymphoma (NHL) patients who received GDP/R-GDP as salvage chemotherapy in our center between July 2014 and January 2020 were retrospectively evaluated. After the evaluation of response, 52 patients had a chemosensitive disease and underwent mobilization with GDP/R-GDP plus G-CSF (granulocyte colony-stimulating factor). Collected CD34+ stem cells and related parameters were compared in terms of diagnosis of HL and NHL, early and late stage, patients who did not receive RT and those who received RT, and patients aged under 60 and over 60. On the 15th day on average (range 11?20), median 8.7 × 106 /kg (4.1 - 41.5) CD34+ stem cells were collected in 51 (98%) of our 52 chemosensitive patients and 1 (2%) patients failed to mobilize. We observed acceptable hematological and non-hematological toxicity. The targeted amount of 2 × 106 /kg CD34+ stem cells was attained by 98% (n: 51) patients, and all of them underwent autologous stem cell transplantation. Moreover, low toxicity profiles provide outpatient utilization option clinics with close follow-up and adequate supportive care. We suggest that GDP/R-GDP plus G-CSF can be used as an effective chemotherapy regimen for mobilizing CD34+ stem cells from peripheral blood in relapsed and refractory lymphoma patients due to low toxicity, effective tumor reduction, and successful stem cell mobilization. It can also be assumed that the GDP mobilization regimen may be more effective, especially in patients with early-stage disease and in HL patients.


  • Open Access

    Efficacy of reduced dose melphalan conditioning for multiple myeloma patients undergoing autologous stem cell transplantation: in the era of combined induction with novel agents

    by Bahar Uncu Ulu, Mehmet Bakirtaş, Tuğçe Nur YİĞENOĞLU, Semih Başci, Jale Yildiz, Derya Şahi̇n, Tahir Darçin, Alparslan Merdi̇n, Hikmetullah Batgi̇, Dicle İskender, et al.

    Introduction / Aim: Melphalan 200 mg/m2 (MEL 200) is known as the standard conditioning regimen for Multiple Myeloma (MM) patients in autologous stem cell transplantation(ASCT). Most of the studies showing the superiority of MEL 200 versus melphalan 140 mg/m2 (MEL 140) were performed in the era of conventional chemotherapies. However, today, several novel agents such as proteasome inhibitors, immunomodulatory agents have been introduced in MM treatment algorithms. There is limited data on the impact of this dose reduction on progression-free survival (PFS) or overall survival (OS). The present study compares MEL 140 and MEL 200 conditioning for ASCT in patients treated with combination therapy of bortezomib‑containing induction. Material and Method: Results of 84 MM patients who underwent ASCT at our center between 2010 and 2018 were analyzed retrospectively. Findings / Results: In the MEL 140 group, PFS was 9 months (%95 CI 2.2-15.8) and OS was 30 months ( %95CI 9.5-50.4), while PFS was 13 months ( %95CI 10.5-15.5) and OS was 34 months( %95CI 6.9-61) in the MEL 200 group. There was no statistically significant difference in PFS and OS between the two groups (p:0.6, p:0.7). Conclusion: Consequently, MEL 140 and MEL 200 were found similar in terms of engraftment duration, transplant-related mortality rate, and survival rates. The idea that similar outcomes in both MEL 140 and MEL 200 group in patients who received combined induction treatment with novel agent suggested that MEL 140 may be used more commonly than the standard approach of MEL 200. ÖZET Giriş: Multipl Myeloma (MM) tedavisinde 200 mg/m2 melfalan (MEL 200) otolog kök hücre nakli (OKHN) için standart hazırlama rejimi olarak kabul edilmiştir. MEL 200’ün 140 mg/m2 melfalan’a (MEL 140) üstünlüğünü gösteren çalışmaların çoğu konvansiyonel kemoterapiler döneminde yapılmıştır. Ancak günümüzde MM tedavisine immünmodulatuvar, proteozome inhibitörü gibi birçok yeni ajan katılmıştır. Bu çalışmada indüksiyon tedavisinde bortezomib içeren kombinasyon tedavisi almış hastaların otolog kök hücre nakli ile konsalidasyonunda MEL 140 ve MEL 200’un karşılaştırılması hedeflendi. Materyal Metot: 2010-2018 yılları arasında merkezimizde OKHN olmuş 84 MM hastasının sonuçları geriye dönük olarak analiz edildi. Bulgular: MEL 140 grubunda progresyonsuz sağkalım (PFS) 9 ay (%95 CI 2.2-15.8), genel sağkalım (OS) 30 ay (%95CI 9.5-50.4) saptanırken MEL 200 grubunda PFS 13 ay ( %95CI 10.5-15.5) , OS 34 ay ( %95CI 6.9-61) saptandı. Her 2 grup arasında PFS ve OS açısından istatistiksel olarak anlamlı bir fark saptanmadı (sırasıyla p:0.6; p:0.7). Sonuç: Sonuç olarak, engraftman süreleri, transplant ilişkili mortalite oranı ve sağkalım oranları açısından MEL 140 ve MEL 200 benzer bulundu. İndüksiyon tedavisinde yeni ajanlar ile kombine tedaviler almış olan hastalarda MEL 140 ve MEL 200 arasında OS ve PFS farkı olmaması, standart yaklaşım olan MEL 200 yerine MEL 140’ın daha yaygın kullanabileceği fikrini doğurmuştur.

  • Open Access

    The effect of smoking on stem cell mobilization in allogeneic donors

    by Tuğçe Nur YİĞENOĞLU, Semih Başci, Derya Şahi̇n, Mehmet Bakirtaş, Ali Kilinc, Bahar Uncu Ulu, Hikmetullah Batgi̇, Dicle İsKender, Nurgul Ozcan, Merih Kizil Çakir, et al.

    Introduction: It has been shown that there is an increase in the number of progenitor cells in the bone marrow after smoking cessation. Adequate number of stem cells should be given to the patients to provide sustained engraftment after allogeneic stem cell transplantation. Therefore, determining the factors affecting the success of peripheral stem cell mobilization in allogenic donors is very important. In this study, we aimed to investigate the effect of smoking on the amount of stem cells collected after peripheral blood stem cell mobilization in allogeneic donors.Material and Method: The data of 157 allogeneic donors who were performed peripheral stem cell mobilization in our center were analyzed retrospectively. The donors were divided into 2 groups:active smokers (n:80) and non-smokers (n:77). Smokers were divided into two groups as donors who smoked <15 cigarette pack year and those who smoked ≥15 cigarette pack year.Results: The median CD34+ cell count in the peripheral blood on the 5th day before apheresis was found to be significantly lower in smokers than in non-smokers (p=0.001*). Compared to the donors who smoked <15 cigarette pack year, the median CD34+ cell count in the peripheral blood on the 5th day before apheresis was significantly lower in the donors who smoked ≥15 cigarette pack year (p=0.009*).Conclusion:During the allogeneic stem cell donor assessment, donors should be questioned for their smoking history. Smoking should be considered as a negative risk factor for peripheral stem cell mobilization, especially in the donors who smoke ≥15 cigarette pack year.